Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antigenics Oncophage Retrospective Testing For Potency Is Approval Issue

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Approval of Antigenics’ Phase III cancer vaccine Oncophage rests on whether FDA will accept retrospective testing of vaccine used in pivotal trials to support product characterization, the company said.

You may also be interested in...

Cell Genesys GVAX Prostate Cancer Vaccine To Start Phase III Second-Quarter

Cell Genesys’ GVAX prostate cancer vaccine is scheduled to enter Phase III at the end of the second quarter under FDA’s special protocol assessment program.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts